RJA
CRDF icon

Ross\Johnson & Associates’s Cardiff Oncology CRDF Stock Holding History

Ross\Johnson & Associates’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1 Hold
1
– – ﹤0.01% 371
2026
Q1 		$2 Hold
1
– – ﹤0.01% 216
2025
Q4 		$3 Hold
1
– – ﹤0.01% 354
2025
Q3 		$2 Hold
1
– – ﹤0.01% 216
2025
Q2 		$3 Hold
1
– – ﹤0.01% 214
2025
Q1 		$3 Hold
1
– – ﹤0.01% 357
2024
Q4 		$4 Buy
+1
New +$3 ﹤0.01% 93

Other funds holding CRDF

LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Ross\Johnson & Associates's CRDF Position: Q2 2026 in Review

Ross\Johnson & Associates held its Cardiff Oncology (CRDF) position steady in Q2 2026 at 1 share worth $1. The position accounts for ﹤0.01% of the portfolio, ranked #371.

Ross\Johnson & Associates first reported a position in CRDF in Q4 2024 and has held it in 7 quarters since. The position peaked at $4 in Q4 2024. 105 funds tracked by Wall St. Rank hold CRDF as of Q2 2026.

  • Ross\Johnson & Associates held 1 share of Cardiff Oncology worth $1 as of Q2 2026.
  • Ross\Johnson & Associates left its Cardiff Oncology share count unchanged in Q2 2026.
  • Cardiff Oncology made up ﹤0.01% of Ross\Johnson & Associates's portfolio in Q2 2026, its #371 holding.
  • Ross\Johnson & Associates first reported a position in Cardiff Oncology in Q4 2024 and has held it in 7 quarters since.
  • Ross\Johnson & Associates's Cardiff Oncology position peaked at $4 in Q4 2024.
  • 105 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2026.

Based on Ross\Johnson & Associates's 13F filing for Q2 2026, filed 14 Aug 2026.